Holen Sie sich die Stockscreener-App
281.00
0.46%
-1.29
Handel nachbörslich:
282.99
1.99
+0.71%
Schlusskurs vom Vortag:
$282.29
Offen:
$282.73
24-Stunden-Volumen:
1.35M
Relative Volume:
0.96
Marktkapitalisierung:
$45.92B
Einnahmen:
$2.86B
Nettoeinkommen (Verlust:
$780.66M
KGV:
59.53
EPS:
4.72
Netto-Cashflow:
$1.20B
1W Leistung:
-0.45%
1M Leistung:
+0.33%
6M Leistung:
+25.99%
1J Leistung:
+53.34%
1-Tages-Spanne:
$281.00
$287.47
1-Wochen-Bereich:
$275.44
$287.47
52-Wochen-Spanne:
$177.41
$291.69
Veeva Systems Inc Stock (VEEV) Company Profile
Firmenname
Veeva Systems Inc
Sektor
Branche
Telefon
925-452-6500
Adresse
4280 HACIENDA DRIVE, PLEASANTON, CA
Vergleichen Sie VEEV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VEEV
Veeva Systems Inc
|
281.00 | 46.13B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
58.01 | 10.01B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
97.08 | 8.42B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
60.25 | 11.54B | 550.17M | 201.35M | 232.07M | 1.00 |
|
WAY
Waystar Holding Corp
|
36.97 | 6.64B | 906.14M | -52.62M | 89.62M | -0.3621 |
Veeva Systems Inc Stock (VEEV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-29 | Bestätigt | Needham | Buy |
| 2025-01-23 | Herabstufung | Goldman | Buy → Sell |
| 2024-12-20 | Eingeleitet | Stephens | Overweight |
| 2024-12-04 | Eingeleitet | Mizuho | Outperform |
| 2024-11-19 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-08 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2024-08-27 | Bestätigt | Citigroup | Buy |
| 2024-07-09 | Eingeleitet | BTIG Research | Buy |
| 2023-10-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-10-13 | Eingeleitet | Jefferies | Buy |
| 2023-06-28 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Truist | Buy → Hold |
| 2023-02-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-04 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-12-06 | Eingeleitet | Cowen | Market Perform |
| 2022-12-02 | Bestätigt | Needham | Buy |
| 2022-10-31 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-10-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2022-06-23 | Eingeleitet | Goldman | Buy |
| 2022-06-21 | Fortgesetzt | Guggenheim | Buy |
| 2022-03-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2022-01-07 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Fortgesetzt | Stifel | Buy |
| 2021-09-02 | Bestätigt | BofA Securities | Buy |
| 2021-09-02 | Bestätigt | JMP Securities | Mkt Outperform |
| 2021-09-02 | Bestätigt | Needham | Buy |
| 2021-09-02 | Bestätigt | UBS | Neutral |
| 2021-07-21 | Eingeleitet | Cowen | Outperform |
| 2021-03-31 | Hochstufung | UBS | Sell → Neutral |
| 2021-01-07 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2020-12-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-10-14 | Fortgesetzt | UBS | Sell |
| 2020-08-28 | Bestätigt | Needham | Buy |
| 2020-07-23 | Eingeleitet | FBN Securities | Outperform |
| 2020-07-07 | Eingeleitet | Stephens | Overweight |
| 2020-06-08 | Eingeleitet | Citigroup | Buy |
| 2020-05-29 | Bestätigt | Needham | Buy |
| 2020-04-13 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-14 | Eingeleitet | Piper Sandler | Overweight |
| 2020-01-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-11-27 | Bestätigt | Canaccord Genuity | Hold |
| 2019-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-08-28 | Bestätigt | Needham | Buy |
| 2019-06-07 | Eingeleitet | Goldman | Neutral |
| 2019-05-30 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2019-05-24 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-04-17 | Bestätigt | Needham | Buy |
| 2019-02-27 | Bestätigt | Needham | Buy |
Alle ansehen
Veeva Systems Inc Aktie (VEEV) Neueste Nachrichten
Veeva's Break from Salesforce: A Strategic Inflection Point for Life Sciences SaaS - AInvest
Veeva Systems (VEEV) Secures Merck Commitment To Enhance Global CRM Capabilities - Yahoo Finance
Veeva Systems Breaks Up With Salesforce, Then Woos Merck - Investor's Business Daily
Merck Adopts Veeva Vault CRM - Contract Pharma
Merck Commits To Veeva’s Vault CRM, Draws Wall Street Cheer: Retail’s Not Enthusiastic - Stocktwits
Merck (MRK) Expands Partnership with Veeva Systems for Enhanced CRM Solutions | MRK Stock News - GuruFocus
Merck commits to Veeva Vault CRM for upcoming product launches - Investing.com India
Merck Commits to Veeva Vault CRM - Veeva
Merck Expands Veeva Partnership: Strategic CRM Deal Ahead of Largest Launch Period in History - Stock Titan
What drives Veeva Systems Inc. stock priceFree Smart Trading Workshop - jammulinksnews.com
Is Veeva Systems Inc. a good long term investmentOverwhelming financial success - PrintWeekIndia
What analysts say about Veeva Systems Inc. stockFree Market Volatility Navigation Tips - Autocar Professional
Smith+Nephew: Unpacking the Critical Roles of Clinical and Medical Affairs - Veeva
Veeva Systems Trading Volume Surges 68.79% to 348th Position Despite Stock Price Decline - AInvest
Veeva Systems (VEEV) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
IBD Stock Of The Day Veeva Systems Is Gearing Up To Take On Salesforce - Investor's Business Daily
Why Veeva Systems Outpaces Salesforce in a Fragmented CRM Market - AInvest
Veeva Systems (NYSE:VEEV) Price Target Raised to $325.00 - MarketBeat
Veeva Systems' Vault CRM Continues to Gain Momentum with Top Biopharma Adoptions and New Features - AInvest
Veeva Systems' Vault CRM Momentum Builds With Top Biopharma Adoptions - Yahoo Finance
Veeva (VEEV) Expands with Astellas and Sarah Cannon in Global CRM and Oncology Trials - MSN
Veeva Systems and Sarah Cannon Partner to Accelerate Cancer Clinical Trials - MSN
Fresenius Medical Care Reduces Commercial Content Approval by 14 Days - Veeva
Should You Invest in Veeva (VEEV) Based on Bullish Wall Street Views? - Yahoo Finance
Clinical Data Management Systems Market Key Players Analysis - openPR.com
Veeva Systems Trading Volume Drops 38 Percent to 338th Rank Despite Stock Price Rise - AInvest
Why Veeva Systems (VEEV) is a Top Growth Stock for the Long-Term - Yahoo Finance
Veeva Systems (NYSE:VEEV): Strongest Q1 Results from the Vertical Software Group - Yahoo Finance
Veeva Systems (VEEV) Suffers a Larger Drop Than the General Market: Key Insights - MSN
12 Best Cloud Stocks to Buy According to Wall Street Analysts - Insider Monkey
Veeva Systems Surges to 185th in Trading Volume with $451 Million Day Despite Stock Decline - AInvest
Veeva Systems: A Promising Force in the Pharma Cloud Computing Landscape - AInvest
Veeva Systems: A Strong Contender in Cloud Computing for Pharma - MSN
Here is What to Know Beyond Why Veeva Systems Inc. (VEEV) is a Trending Stock - MSN
Veeva Expands Market Reach Through Targeted Strategic Partnerships - sharewise.com
Veeva Systems (VEEV): Powering MedTech's Clinical Revolution with Data and Compliance - AInvest
Veeva MedTech adoption boosts clinical trials - MarketScreener
VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait? - Yahoo Finance
Veeva Systems: Growth Momentum Remains Strong (NYSE:VEEV) - Seeking Alpha
Veeva Systems: Solid Performance, Terrible Price (NYSE:VEEV) - Seeking Alpha
Veeva Systems (VEEV) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Veeva's impact on compliance and efficiency in medtech - Today's Medical Developments
Veeva Systems Inc. Advances Infant Nutrition with Glycoprotein Formula Study - TipRanks
Here's Why Veeva Systems (VEEV) is a Strong Momentum Stock - Yahoo Finance
Veeva (VEEV) Up 0.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Salesforce vs. Veeva: Which Cloud CRM Stock Is the Smarter Buy? - The Globe and Mail
AWS Powers 50+ Veeva Apps: Tech Giants Deepen 10-Year Cloud Partnership for Life Sciences - Stock Titan
Finanzdaten der Veeva Systems Inc-Aktie (VEEV)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.87%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):